Surgery in GIST
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.
Schema
Summary
The GIST Surgical study is an EORTC-led study. It will assess the impact of adjuvant surgery on progression-free survival time in patients with GIST who have experienced complete response, partial response or stable disease following 6 - 12 months of treatment with imatinib. Patients will be randomized to receive surgery or not.
